Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study.
[BACKGROUND] To evaluate the efficacy and safety of a chemotherapy-free regimen consisting of monoclonal antibody trastuzumab, tyrosine kinase inhibitor pyrotinib, and CDK4/6 inhibitor dalpiciclib in
- 95% CI 45.5-78.1
- 추적기간 20 months
APA
Xiao Z, Chen F, et al. (2026). Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study.. International journal of surgery (London, England), 112(1), 865-872. https://doi.org/10.1097/JS9.0000000000003328
MLA
Xiao Z, et al.. "Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study.." International journal of surgery (London, England), vol. 112, no. 1, 2026, pp. 865-872.
PMID
40968745
Abstract
[BACKGROUND] To evaluate the efficacy and safety of a chemotherapy-free regimen consisting of monoclonal antibody trastuzumab, tyrosine kinase inhibitor pyrotinib, and CDK4/6 inhibitor dalpiciclib in patients with hormone receptor-negative/HER2-positive (HR-HER2+) early breast cancer (EBC).
[MATERIALS AND METHODS] This open-label, single-arm, phase II study was designed using the Simon two-stage method (Registration Number: Chi-CTR-2200060748). Patients with operable HR-HER2+ EBC (T1-3 and N0-2) were enrolled. Eligible patients received trastuzumab (HLX02, 8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks intravenously), pyrotinib (400 mg daily orally), and dalpiciclib (125 mg daily orally for 3 weeks, followed by 1 week off) for 16 weeks. Surgery was performed 3-6 weeks after the completion of drug treatment. The primary endpoint was total pathological complete response (tpCR, ypT0/Tis, and ypN0) rates at surgery, and secondary endpoints included breast pCR (bpCR) rates (ypT0/Tis), residual cancer burden (RCB), objective response rate (ORR), change of Ki-67 scores, survival, and safety.
[RESULTS] Between June 2022 and June 2024, a total of 34 patients with a median age of 55 years (range: 35-67) were enrolled. Thirty patients received all cycles of treatment and underwent surgery with a median follow-up of 20 months. The tpCR was achieved in 19 patients (63.3%; 95% CI, 45.5-78.1%). The bpCR was 66.7% (20/30). The number of patients with RCB-0 or RCB-I was 22 (73.3%). The most common Grade 3 treatment-related adverse events were diarrhea (50.0%), neutropenia (20.6%), and leukopenia (17.7%). No Grade 4 events or treatment-related deaths occurred.
[CONCLUSION] In patients with HR-HER2+ EBC, the neoadjuvant therapy with trastuzumab, pyrotinib, and dalpiciclib has promising activity and manageable toxicity. Further investigation is needed.
[MATERIALS AND METHODS] This open-label, single-arm, phase II study was designed using the Simon two-stage method (Registration Number: Chi-CTR-2200060748). Patients with operable HR-HER2+ EBC (T1-3 and N0-2) were enrolled. Eligible patients received trastuzumab (HLX02, 8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks intravenously), pyrotinib (400 mg daily orally), and dalpiciclib (125 mg daily orally for 3 weeks, followed by 1 week off) for 16 weeks. Surgery was performed 3-6 weeks after the completion of drug treatment. The primary endpoint was total pathological complete response (tpCR, ypT0/Tis, and ypN0) rates at surgery, and secondary endpoints included breast pCR (bpCR) rates (ypT0/Tis), residual cancer burden (RCB), objective response rate (ORR), change of Ki-67 scores, survival, and safety.
[RESULTS] Between June 2022 and June 2024, a total of 34 patients with a median age of 55 years (range: 35-67) were enrolled. Thirty patients received all cycles of treatment and underwent surgery with a median follow-up of 20 months. The tpCR was achieved in 19 patients (63.3%; 95% CI, 45.5-78.1%). The bpCR was 66.7% (20/30). The number of patients with RCB-0 or RCB-I was 22 (73.3%). The most common Grade 3 treatment-related adverse events were diarrhea (50.0%), neutropenia (20.6%), and leukopenia (17.7%). No Grade 4 events or treatment-related deaths occurred.
[CONCLUSION] In patients with HR-HER2+ EBC, the neoadjuvant therapy with trastuzumab, pyrotinib, and dalpiciclib has promising activity and manageable toxicity. Further investigation is needed.
MeSH Terms
Humans; Female; Breast Neoplasms; Trastuzumab; Middle Aged; Neoadjuvant Therapy; Adult; Acrylamides; Aged; Erb-b2 Receptor Tyrosine Kinases; Antineoplastic Combined Chemotherapy Protocols; Aminoquinolines; Treatment Outcome; Piperidines; Pyridines; Pyrimidines
같은 제1저자의 인용 많은 논문 (5)
- A Dual-phase Enhanced CT-based Nomogram for Predicting the Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
- Case Report: Co-existence of gene fusion and variants in myeloid neoplasm with persistent leukocytosis, large splenomegaly, and eosinophilia.
- Mechanism by which Icariin suppresses pulmonary metastasis in triple-negative breast cancer through downregulation of the SPDL1/JAK2/STAT3 signaling pathway.
- Engineered bacterial extracellular vesicles mediate pyroptosis to counteract mA methylation-based immunosuppression after insufficient radiofrequency ablation of hepatocellular carcinoma.
- Hepatocellular Carcinoma Presenting as Bile Duct Tumor Thrombus without Obvious Intrahepatic Mass.